Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke

Summary

The aim of this study was to assess whether triple antiplatelet therapy is superior to dual and mono therapy in attenuating platelet and leucocyte function. Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials. At the end of each two-week period platelet aggregation, platelet-leucocyte conjugate formation and leucocyte activation were measured ex vivo blinded to treatment. Platelets were stimulated with collagen; additional measurements were made with adenosine diphosphate (ADP), platelet activating factor (PAF), adrenaline and the combination of, ADP, PAF and adrenaline. Results show that in the presence of collagen, ACD was superior to all antagonists or combinations, except AC, in reducing aggregation, platelet-leucocyte conjugate formation, and monocyte activation (all p< 0.05). ACD was also more potent than other treatments, except AC, in inhibiting the aggregation and platelet-monocyte conjugate formation induced by the combination of ADP, PAF and adrenaline. The effects were similar in both volunteers and stroke patients. No serious adverse events or major bleeding events occurred. Triple antiplatelet therapy did not appear to be more effective than combined aspirin and clopidogrel in moderating platelet and leucocyte function. Any additional clinical benefit provided by dipyridamole may be through other mechanisms of action.

Keywords

Aspirin - clopidogrel - dipyridamole - platelets - ischaemic stroke

• References

• 1 Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 2 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
• 3 Diener HC, Cunha L, Forbes C. et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
• 4 Yusuf S, Fox KAA, Tognoni G. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 5 Steinhubl SR, Berger PB, Mann , 3rd JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
• 6 Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134: 353-8.
• 7 Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22.
• 8 Rinder H, Bonan JL, Rinder CS. et al. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991; 78: 1760-9.
• 9 Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 2004; 92: 1086-94.
• 10 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
• 11 Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
• 12 da Costa Martins P, van den Berk N, Ulfman LH. et al. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler Thromb Vasc Biol 2004; 24: 193-9.
• 13 Ott I, Neumann FJ, Gawaz M. et al. Increase neutrophil- platelet adhesion in patients with unstable angina. Platelets 1996; 94: 1239-46.
• 14 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.
• 15 Furman I M, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-6.
• 16 Caimi G, Canino B, Ferrara F. et al. Granulocyte integrins before and after activation in acute ischaemic stroke. J Neurol Sci 2001; 186: 23-6.
• 17 Harding SA, Sarma J, Josephs DH. et al. Upregulation of the CD40/CD40 ligand dyad and plateletmonocyte aggregation in cigarette smokers. Circulation 2004; 109: 1926-1929.
• 18 Zhao L, Bath PMW, Fox S. et al. The effects of GPII-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003; 19: 178-86.
• 19 Nurden AT, Nurden P. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin Haematol 1993; 6: 653-90.
• 20 Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602-12.
• 21 van der Poll T, Jansen J, Endert E. et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994; 62: 2046-50.
• 22 Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000; 39: 41-82.
• 23 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
• 24 Grau AJ, Reiners S, Lichy C. et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. A case-crossover study. Stroke 2003; 34: 849-55.
• 25 Muller TH, Weisenberger H, Brickl R. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-86.
• 26 Delanty N, Vaughan CJ. Vascular Effects of Statins in Stroke. Stroke 1997; 28: 2315-20.
• 27 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
• 28 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
• 29 Bath P. Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key. Stroke 2003; 34: 1334-1335.
• 30 Lugnier C, Schoeffter P, Le Bec A. et al. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743-51.
• 31 Bult H, Fret HR, Jordaens FH. et al. Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost 1991; 66: 343-9.
• 32 Bult H, Fret HR, Jordaens FH. et al. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991; 199: 1-8.
• 33 Ziegler JW, Ivy DD, Fox JJ. et al. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. Am J Respir Crit Care Med 1998; 157: 1104-10.
• 34 Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel walls cells. Neurology 2001; 57 (Suppl. 02) S20-S23.
• 35 Eisert WG. Dipyridamole. In: Michelson, ed. Platelets 2002; Academic Press 803-815.
• 36 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and the secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741-9.
• 37 Stafford NP, Pink AE, White AE. et al. Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood. Arterioscler Thromb Vasc Biol 2003; 23: 1928-33.
• 38 Zhao L, Leonardi-Bee J, Weaver C. et al. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular stress in patients with prior stroke. 5th World Stroke Congress. 2004: V ancouver, B.C; Canada: Abstract
• 39 Willmot M, Zhao L, Heptinstall S. et al. Triple antiplatelet therapy for secondary prevention of recurrent ischaemic stroke. J Stroke Cerebrovasc Dis 2004; 13: 138-40.
• 40 Zhao L, Fletcher S, Weaver C. et al. Effect of combined aspirin, clopidogrel and dipyridamole on platelet aggregation, platelet-leucocyte conjugates and leucocyte activation ex vivo: phase I study. In: 7th International symposium on thrombolysis and acute stroke therapy 2002; 64 (abstract)